An Exploratory Phase 2 Study of Neoadjuvant Chemotherapy Followed by Stereotactic Body Radiation Therapy (SBRT) With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable Pancreatic Cancer

Trial Profile

An Exploratory Phase 2 Study of Neoadjuvant Chemotherapy Followed by Stereotactic Body Radiation Therapy (SBRT) With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable Pancreatic Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2016

At a glance

  • Drugs Agenmestencel-L (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors NewLink Genetics Corporation
  • Most Recent Events

    • 30 Jun 2016 Status changed from active, no longer recruiting to discontinued.
    • 31 May 2016 Status changed from recruiting to active, no longer recruiting.
    • 28 May 2015 According to the ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top